PE20030361A1 - Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas - Google Patents
Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activasInfo
- Publication number
- PE20030361A1 PE20030361A1 PE2002000742A PE2002000742A PE20030361A1 PE 20030361 A1 PE20030361 A1 PE 20030361A1 PE 2002000742 A PE2002000742 A PE 2002000742A PE 2002000742 A PE2002000742 A PE 2002000742A PE 20030361 A1 PE20030361 A1 PE 20030361A1
- Authority
- PE
- Peru
- Prior art keywords
- agents
- butyl
- alkyl
- methyl
- inhibiting agents
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000013543 active substance Substances 0.000 title abstract 3
- -1 ETHYL PROPYL Chemical group 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical group [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Abstract
SE REFIERE FORMULACIONES EN COMBINACION DE DERIVADOS DE 1,4-BENZOTIEPINA-1,1-DIOXIDO DE FORMULA I DONDE R1 ES METILO, ETILO PROPILO, BUTILO; R2 ES H, OH, NH2, NH-ALQUILO(C1-C6); R3 ES UN RADICAL AZUCAR, UNA RADICAL AMINOACIDO, UN DIAMINOACIDO, CON GRUPOS PROTECTORES DE AZUCARES Y AMINOACIDOS; R4 ES METILO, ETILO, PROPILO, BUTILO; R5 ES METILO, ETILO, PROPILO, BUTILO; Z ES -(C=O)n-ALQUILO C0-C16, -(C=O)n-ALQUIL C0-C16-NH-, ENTRE OTROS; n ES 0-1; m ES 0-1. SE REFIERE TAMBIEN A UNA MEZCLA DE SUSTANCIAS QUE COMPRENDE LA SUSTANCIA ACTIVA JUNTO A AGENTES ANTIDIABETICOS , SUSTANCIAS ACTIVAS HIPOGLUCEMICAS, AGENTES INHIBIDORES DE HMG-CoA-REDUCTASA, AGENTES INHIBIDORES DE LA RESORCION DEL COLESTEROL (EZETIMIBE, TIQUESIDE, PAMAQUESIDE), AGENTES INHIBIDORES DE MTP, ANTIOXIDANTES, INHIBIDORES DE SINTETASA ESCUALENO. LA FORMULACION ES UTIL PARA EL TRATAMIENTO DE HIPERLIPIDEMIA, TRASTORNOS DEL METABOLISMO DE LIPIDOS, ARTERIOESCLEROSIS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10140169A DE10140169A1 (de) | 2001-08-22 | 2001-08-22 | Kombinationspräparate von 1,4-Benzothiepin-1,1-dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung |
| DE10142456A DE10142456A1 (de) | 2001-08-31 | 2001-08-31 | Kombinationspräparate von 1,4-Benzothiepin-1,1dioxidderivaten mit weiteren Wirkstoffen und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030361A1 true PE20030361A1 (es) | 2003-05-27 |
Family
ID=26009944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000742A PE20030361A1 (es) | 2001-08-22 | 2002-08-16 | Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20030158119A1 (es) |
| EP (1) | EP1425018B1 (es) |
| JP (1) | JP2005501861A (es) |
| KR (1) | KR20040032937A (es) |
| CN (1) | CN1655792A (es) |
| AR (1) | AR035285A1 (es) |
| AT (1) | ATE411802T1 (es) |
| AU (1) | AU2002333373B2 (es) |
| BR (1) | BR0212031A (es) |
| CA (1) | CA2457976A1 (es) |
| CO (1) | CO5560550A2 (es) |
| DE (1) | DE50212937D1 (es) |
| HN (1) | HN2002000235A (es) |
| HR (1) | HRP20040171A2 (es) |
| HU (1) | HUP0401318A3 (es) |
| IL (1) | IL160474A0 (es) |
| MA (1) | MA26317A1 (es) |
| MX (1) | MXPA04001328A (es) |
| NO (1) | NO20040702L (es) |
| NZ (1) | NZ531293A (es) |
| OA (1) | OA12654A (es) |
| PA (1) | PA8553201A1 (es) |
| PE (1) | PE20030361A1 (es) |
| PL (1) | PL366851A1 (es) |
| RS (1) | RS11104A (es) |
| RU (1) | RU2297222C2 (es) |
| TN (1) | TNSN04034A1 (es) |
| UY (1) | UY27419A1 (es) |
| WO (1) | WO2003018024A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| HU230253B1 (hu) | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| ME00145B (me) | 2001-01-26 | 2010-10-10 | Merck Sharp & Dohme | Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| ATE406364T1 (de) | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
| WO2004081003A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| DE102006053637B4 (de) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE102006053635B4 (de) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| JP2010509252A (ja) | 2006-11-14 | 2010-03-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 改善された特性を有する新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物、及びそれらの使用 |
| DE102006053636B4 (de) * | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
| CN102316872B (zh) | 2008-11-26 | 2016-12-21 | 萨蒂奥根制药公司 | 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂 |
| EP2575821B1 (en) * | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| EP2765855A4 (en) | 2011-10-12 | 2015-03-25 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS FOR DISPERSION INHIBITION |
| EP3278796A1 (en) | 2011-10-28 | 2018-02-07 | Lumena Pharmaceuticals LLC | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| EP3266457A1 (en) | 2011-10-28 | 2018-01-10 | Lumena Pharmaceuticals LLC | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| JP2016514684A (ja) | 2013-03-15 | 2016-05-23 | ルメナ ファーマシューティカルズ エルエルシー | 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤 |
| MX2015013196A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett. |
| KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| AU2020221239A1 (en) | 2019-02-12 | 2021-09-16 | Mirum Pharmaceuticals, Inc. | Methods for treating cholestasis |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| KR19990077319A (ko) | 1996-01-17 | 1999-10-25 | 한센 핀 베네드, 안네 제헤르 | 축합된 1,2,4-티아디아진 및 축합된 1,4-티아진 유도체, 그것의제조방법 및 사용 |
| WO1997041097A2 (en) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| DE69737479T4 (de) | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| EP1000066A1 (en) | 1997-07-16 | 2000-05-17 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
| DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| BR9916564A (pt) * | 1998-12-23 | 2002-01-29 | Searle Llc | Combinações para indicações cardiovasculares |
| GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
| EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| CA2371271A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands |
| GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
| JP2003502369A (ja) | 1999-06-18 | 2003-01-21 | メルク エンド カムパニー インコーポレーテッド | アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体 |
| EP1204654B1 (en) | 1999-07-29 | 2003-07-23 | Eli Lilly And Company | Benzofurylpiperazines: 5-ht2c serotonin receptor agonists |
| PL353367A1 (en) | 1999-09-01 | 2003-11-17 | Aventis Pharma Deutschland Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
| KR100502876B1 (ko) | 2000-04-28 | 2005-07-21 | 아사히 가세이 파마 가부시키가이샤 | 신규 이환성 화합물 |
| DE60115227T2 (de) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| WO2001091752A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
| IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
-
2002
- 2002-08-09 AU AU2002333373A patent/AU2002333373B2/en not_active Ceased
- 2002-08-09 MX MXPA04001328A patent/MXPA04001328A/es active IP Right Grant
- 2002-08-09 IL IL16047402A patent/IL160474A0/xx unknown
- 2002-08-09 BR BR0212031-3A patent/BR0212031A/pt not_active IP Right Cessation
- 2002-08-09 JP JP2003522542A patent/JP2005501861A/ja active Pending
- 2002-08-09 CA CA002457976A patent/CA2457976A1/en not_active Abandoned
- 2002-08-09 WO PCT/EP2002/008908 patent/WO2003018024A1/de not_active Ceased
- 2002-08-09 HR HR20040171A patent/HRP20040171A2/xx not_active Application Discontinuation
- 2002-08-09 RS YU11104A patent/RS11104A/sr unknown
- 2002-08-09 DE DE50212937T patent/DE50212937D1/de not_active Expired - Lifetime
- 2002-08-09 RU RU2004108119/15A patent/RU2297222C2/ru not_active IP Right Cessation
- 2002-08-09 HU HU0401318A patent/HUP0401318A3/hu unknown
- 2002-08-09 PL PL02366851A patent/PL366851A1/xx not_active Application Discontinuation
- 2002-08-09 KR KR10-2004-7002440A patent/KR20040032937A/ko not_active Ceased
- 2002-08-09 CN CNA028163109A patent/CN1655792A/zh active Pending
- 2002-08-09 AT AT02796213T patent/ATE411802T1/de not_active IP Right Cessation
- 2002-08-09 OA OA1200400057A patent/OA12654A/en unknown
- 2002-08-09 EP EP02796213A patent/EP1425018B1/de not_active Expired - Lifetime
- 2002-08-09 NZ NZ531293A patent/NZ531293A/en not_active IP Right Cessation
- 2002-08-16 PE PE2002000742A patent/PE20030361A1/es not_active Application Discontinuation
- 2002-08-20 AR ARP020103125A patent/AR035285A1/es not_active Application Discontinuation
- 2002-08-20 UY UY27419A patent/UY27419A1/es unknown
- 2002-08-20 HN HN2002000235A patent/HN2002000235A/es unknown
- 2002-08-20 PA PA20028553201A patent/PA8553201A1/es unknown
- 2002-08-22 US US10/225,841 patent/US20030158119A1/en not_active Abandoned
-
2003
- 2003-11-03 US US10/699,967 patent/US7179792B2/en not_active Expired - Lifetime
-
2004
- 2004-02-11 MA MA27524A patent/MA26317A1/fr unknown
- 2004-02-18 NO NO20040702A patent/NO20040702L/no not_active Application Discontinuation
- 2004-02-19 CO CO04014418A patent/CO5560550A2/es not_active Application Discontinuation
- 2004-02-20 TN TNP2004000034A patent/TNSN04034A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL160474A0 (en) | 2004-07-25 |
| CN1655792A (zh) | 2005-08-17 |
| CO5560550A2 (es) | 2005-09-30 |
| NZ531293A (en) | 2005-08-26 |
| HN2002000235A (es) | 2003-02-18 |
| NO20040702L (no) | 2004-05-19 |
| OA12654A (en) | 2006-06-15 |
| HUP0401318A2 (hu) | 2004-10-28 |
| RU2004108119A (ru) | 2005-04-10 |
| PA8553201A1 (es) | 2004-08-31 |
| EP1425018A1 (de) | 2004-06-09 |
| MA26317A1 (fr) | 2004-10-01 |
| JP2005501861A (ja) | 2005-01-20 |
| ATE411802T1 (de) | 2008-11-15 |
| PL366851A1 (en) | 2005-02-07 |
| AR035285A1 (es) | 2004-05-05 |
| WO2003018024A1 (de) | 2003-03-06 |
| AU2002333373B2 (en) | 2006-12-14 |
| US7179792B2 (en) | 2007-02-20 |
| TNSN04034A1 (en) | 2006-06-01 |
| UY27419A1 (es) | 2003-04-30 |
| RU2297222C2 (ru) | 2007-04-20 |
| HUP0401318A3 (en) | 2008-03-28 |
| US20030158119A1 (en) | 2003-08-21 |
| HRP20040171A2 (en) | 2004-10-31 |
| US20040097424A1 (en) | 2004-05-20 |
| EP1425018B1 (de) | 2008-10-22 |
| DE50212937D1 (de) | 2008-12-04 |
| MXPA04001328A (es) | 2004-05-05 |
| KR20040032937A (ko) | 2004-04-17 |
| RS11104A (sr) | 2006-12-15 |
| BR0212031A (pt) | 2004-08-03 |
| CA2457976A1 (en) | 2003-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030361A1 (es) | Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas | |
| MXPA03011981A (es) | 3-fluoruro-pirrolidinas como agentes antidiabeticos. | |
| EE200100558A (et) | Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine | |
| UA66825C2 (uk) | Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності | |
| AP9801169A0 (en) | N-hydroxy-B-sulfonyl propionamide derivatives. | |
| AU4264396A (en) | Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof | |
| MXPA04000577A (es) | Derivados de dolastatina 10. | |
| FI963398A0 (fi) | Kielenalainen tai poskensisäinen farmaseuttinen koostumus | |
| NO914356L (no) | Mono n-substituerte 1,4,7,10-tetraazacyklododekanderivater, fremgangsmaater for fremstilling av dem og farmasoeytiskemidler som inneholder dem | |
| IL115920A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING omega-SUBSTITUTED 2,2-DICHLOROALKANECARBOXYLIC ACIDS, SOME SUCH NEW COMPOUNDS AND PROCESS FOR THEIR PREPARATION | |
| AU2505297A (en) | Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect | |
| GR3036606T3 (en) | Pyrimidine or triazine carboxylic acid derivatives to be used as medicaments | |
| IL148874A0 (en) | Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them | |
| TW200735864A (en) | Immediate release pharmaceutical formulation | |
| IL159412A0 (en) | A synergistic pharmaceutical combination for the prevention or treatment of diabetes | |
| IL131216A (en) | Drugs inhibiting progress of pterygium and postoperative recurrence of the same | |
| ATE212996T1 (de) | Anthracyclin-derivate | |
| ATE161178T1 (de) | Pyrazolpyridine für die behandlung der anämie | |
| ES2058085T3 (es) | Composicion anticonvulsivante que contiene un derivado de aminoacido, y utilizacion de dicho derivado de aminoacido. | |
| AR020294A1 (es) | COMPUESTOS DERIVADOS DE 1-TRIFLUOROMETIL-4-HIDROXI-7-PIPERIDINIL-AMINOMETILCROMANO, COMPOSICION FARMACEUTICA Y USO EN LA PREPARACIoN DE MEDICAMENTOS. | |
| NZ510116A (en) | Tricyclic delta-3-piperidines as pharmaceuticals | |
| SE9202218D0 (sv) | Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation | |
| AU9080398A (en) | Novel diamine alkylene diacetic or triacetic acid derivatives, preparation method, use in cosmetic and pharmaceutical compositions and compositions containing them | |
| TR200001122T2 (tr) | Farmasötikler olarak bifenil türevleri. | |
| GEP20074100B (en) | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |